Amphastar Pharma (AMPH) Tops Q2 EPS by 2c

Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $53.85 million versus the consensus estimate of $55.7 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• Amrize Ltd (AMRZ) PT Lowered to $42 at UBS on Lower Earnings Estimates
• UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period